Argus
•
Apr 22, 2026
PTGX: Raising target price to $111.00
Summary
Protagonist Therapeutics Inc is a clinical-stage biopharmaceutical company having a proprietary technology platform that enables the discovery and development of novel constrai
Upgrade to begin using premium research reports and get so much more.
Exclusive reports, detailed company profiles, and best-in-class trade insights to take your portfolio to the next level
UpgradeRelated Reports
Analyst Report: Bristol-Myers Squibb Company
Apr 30, 2026
•
BMY
APLS: What does Argus have to say about APLS?
Apr 29, 2026
•
APLS
RCUS: What does Argus have to say about RCUS?
Apr 29, 2026
•
RCUS
KRYS: Lowering target price to $296.00
Apr 29, 2026
•
KRYS
APLS: What does Argus have to say about APLS?
Apr 22, 2026
•
APLS
